Search

Your search keyword '"Cany L"' showing total 127 results
Start Over Author "Cany L"
127 results on '"Cany L"'

1. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

Author

Smith, D., Tubiana-Mathieu, N., Michel, P., Guimbaud, R., Becouarn, Y., Viret, F., Larregain-Fournier, D., Botreau, Y., Texereau, P., Auby, D., Gautier-Felizot, L., Loury-Larivière, I., Brudieux, E., Cany, L., Lecaille, C., Jaubert, D., Guichard, P., Bernard, O., Vives, L., Taoubi, N., Martinez, M., Burki, F., Roque, I., Thouveny, F., Gaspard, M.H., Gouverneur, Amandine, Coutureau, Juliette, Jové, Jérémy, Rouyer, Magali, Grelaud, Angela, Duc, Sophie, Gérard, Stéphane, Smith, Denis, Ravaud, Alain, Droz, Cécile, Bernard, Marie-Agnès, Lassalle, Régis, Forrier-Réglat, Annie, and Noize, Pernelle

Published
2019
Full Text
View/download PDF

2. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

3. LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial

Author

Lepage, C., primary, Phelip, J.M., additional, Cany, L., additional, Barbier, E., additional, Manfredi, S., additional, Deguiral, P., additional, Faroux, R., additional, Baconnier, M., additional, Pezet, D., additional, Terrebonne, E., additional, Adenis, A., additional, Ben Abdelghani, M., additional, Ain, J.F., additional, Breysacher, G., additional, Benedetto, I. Boillot, additional, Pelaquier, A., additional, Lievre, A., additional, Puig, P. Laurent, additional, Bibeau, F., additional, and Bouche, O., additional

Published
2022
Full Text
View/download PDF

5. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

Author

Aparicio, T., Bouché, O., Etienne, P. L., Barbier, E., Mineur, L., Desgrippes, R., Guerin-Meyer, V., Hocine, F., Martin, J., Le Brun-Ly, V., Cretin, J., Desramé, J., Rinaldi, Y., Cany, L., Falandry, C., Lefevre, L. B., Marous, M., Terrebonne, E., Mosser, L., Turpin, J., Turpin, A., Bauguion, L., Reichling, C., Eynde, M., Carola, E., Hiret, S., UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, CarMeN, laboratoire, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Privé des Côtes d'Armor (HPCA), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Service Biostatistiques et Informatique Médicale (CHU de Dijon) (DIM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Fédération Francophone de Cancérologie Digestive (FFCD), Institut Sainte Catherine [Avignon], CH de Saint-Malo [Broussais], Service d'Oncologie Médicale [Angers], Centre Paul Papin, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Centre Hospitalier Simone Veil de Beauvais [Beauvais], Clinique François Chénieux, Hôpital Dupuytren [CHU Limoges], Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), Hôpital privé Jean Mermoz [Lyon], Hôpital Européen [Fondation Ambroise Paré - Marseille], Clinique Francheville [Périgueux], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service d'oncogénétique [Centre georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, CHU de la Martinique [Fort de France], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital Jacques Puel - Bourran [Rodez] (HJPB), Clinique Sainte Isabelle [Abbeville, France], Service d'oncologie médicale (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), CH Colmar, Cliniques Universitaires Saint-Luc [Bruxelles], Groupe Hospitalier Public du Sud de l'Oise [Creil] (GHPSO), CRLCC René Gauducheau, and Département d'oncologie médicale [Saint Herblain]

Subjects
Geriatric evaluation, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Hepatology, Older, Gastroenterology, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Adjuvant chemotherapy, Colon cancer
Abstract

International audience; BACKGROUND: Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection, but this improvement was not demonstrated in older patients. METHODS: The purpose of ADAGE-PRODIGE 34, randomized open phase III trial is to compare in patients over 70 years oxaliplatin plus fluoropyrimidine with fluoropyrimidine alone in fit patients (Group 1) and fluoropyrimidine with observation in frail patients (Group 2) after resection of stage III colon adenocarcinoma. We report a preliminary tolerance analysis on 50% of the first patients enrolled. RESULTS: The analysis was conducted on 491 patients (378 in Group 1 and 113 in Group 2). Patients in Group 2 were older and showed more frailty criteria than those in Group 1. Cumulative grade 3-5 toxicities were more frequent in patients treated with oxaliplatin in Group 1 or with fluoropyrimidine in Group 2 than in patients treated with fluoropyrimidine in Group 1. At least one course was deferred in more than half of the patients in all groups. Early treatment cessation was more frequent in Group 2. CONCLUSION: No safety concerns were raised for the continuation of accrual. The frailty criteria distribution suggests that the investigator's evaluation for group allocation was accurate.

Published
2022
Full Text
View/download PDF

8. 394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial

Author

Aparicio, T., primary, Bouche, O., additional, Etienne, P.L., additional, Barbier, E., additional, Mineur, L., additional, Desgrippes, R., additional, Hocine, F., additional, Martin, J.J., additional, Lebrun-Ly, V., additional, Crétin, J., additional, Desrame, J., additional, Rinaldi, Y., additional, Cany, L., additional, Falandry, C., additional, Terrebonne, E., additional, Mosser, L., additional, Pauwels, M., additional, Turpin, A., additional, Van den Eynde, M., additional, and Hiret, S., additional

Published
2021
Full Text
View/download PDF

9. 394P Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, Aparicio, T., Bouche, O., Etienne, P.L., Barbier, E., Mineur, L., Desgrippes, R., Hocine, F., Martin, J.J., Lebrun-Ly, V., Crétin, J., Desrame, J., Rinaldi, Y., Cany, L., Falandry, C., Terrebonne, E., Mosser, L., Pauwels, M., Turpin, A., Van den Eynde, Marc, Hiret, S., UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Service d'hépato-gastro-entérologie, Aparicio, T., Bouche, O., Etienne, P.L., Barbier, E., Mineur, L., Desgrippes, R., Hocine, F., Martin, J.J., Lebrun-Ly, V., Crétin, J., Desrame, J., Rinaldi, Y., Cany, L., Falandry, C., Terrebonne, E., Mosser, L., Pauwels, M., Turpin, A., Van den Eynde, Marc, and Hiret, S.

Abstract

Background Colon adenocarcinoma occurs mainly in older patients (pts). Oxaliplatin based adjuvant chemotherapy has demonstrated an improvement on disease-free survival (DFS) after a stage III colon cancer resection in young pts. Nevertheless, the benefit of adjuvant chemotherapy is matter of debate in old pts. Methods The purpose of ADAGE trial is to compare the DFS obtain with oxaliplatin combined with fluoropyrimidine (F) to F alone in fit pts over 70 years (group 1) and F to observation in frail pts (group 2) after resection of a stage III colon cancer. We here report a preliminary tolerance analysis on 50% of the first pts enrolled in the study. Results The analysis was performed on 491 pts (378 in group 1 and 113 in group 2). Main pts characteristics were respectively for the group 1 and 2: male in 57% and 50%, median age of 76 and 83 years, ECOG=0 in 59% and 29%, abnormal IADL in 23% and 62%, no caregiver in 26% and 28%, fall ≤6 months in 9% and 14%, depression possible 28% and 40%, fail of one-leg balance in 20% and 59%, impaired cognition in 21% and 38%, G8 score <14 75% and 94%, undernutrition 35% and 48%. The toxicity was reported in the 434 pts treated excluding the 57 pts in observation arm of group 2. One treatment related death was reported in the doublet chemotherapy arm of group 1.

Published
2021

11. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer

Author

Bécouarn, Y., Senesse, P., Thézenas, S., Boucher, E., Adenis, A., Cany, L., Jacob, J.H., Cvitkovic, F., Montoto-Grillot, C., and Ychou, M.

Published
2007
Full Text
View/download PDF

12. 398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial

Author

Lepage, C., primary, Phelip, J.M., additional, Cany, L., additional, Barbier, E., additional, Manfredi, S., additional, Deguiral, P., additional, Faroux, R., additional, Baconnier, M., additional, Pezet, D., additional, Duchmann, J., additional, Terrebonne, E., additional, Adenis, A., additional, Benabdelghani, M., additional, Ain, J., additional, Breysacher, G., additional, Boillot-Benedetto, I., additional, Pelaquier, A., additional, Prost, P., additional, Lievre, A., additional, and Bouche, O., additional

Published
2020
Full Text
View/download PDF

14. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

Author

Gouverneur, Amandine, primary, Coutureau, Juliette, additional, Jové, Jérémy, additional, Rouyer, Magali, additional, Grelaud, Angela, additional, Duc, Sophie, additional, Gérard, Stéphane, additional, Smith, Denis, additional, Ravaud, Alain, additional, Droz, Cécile, additional, Bernard, Marie-Agnès, additional, Lassalle, Régis, additional, Forrier-Réglat, Annie, additional, Noize, Pernelle, additional, Smith, D., additional, Tubiana-Mathieu, N., additional, Michel, P., additional, Guimbaud, R., additional, Becouarn, Y., additional, Viret, F., additional, Larregain-Fournier, D., additional, Botreau, Y., additional, Texereau, P., additional, Auby, D., additional, Gautier-Felizot, L., additional, Loury-Larivière, I., additional, Brudieux, E., additional, Cany, L., additional, Lecaille, C., additional, Jaubert, D., additional, Guichard, P., additional, Bernard, O., additional, Vives, L., additional, Taoubi, N., additional, Martinez, M., additional, Burki, F., additional, Roque, I., additional, Thouveny, F., additional, and Gaspard, M.H., additional

Published
2019
Full Text
View/download PDF

15. Abstract GS2-07: PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

Author

Pivot, X, primary, Romieu, G, additional, Debled, M, additional, Pierga, J-Y, additional, Kerbrat, P, additional, Bachelot, T, additional, Espie, M, additional, Lortholary, A, additional, Fumoleau, P, additional, Serin, D, additional, Jacquin, J-P, additional, Jouannaud, C, additional, Rios, M, additional, Abadie-Lacourtoisie, S, additional, Venat-Bouvet, L, additional, Cany, L, additional, Catala, S, additional, Khayat, D, additional, Gambotti, L, additional, Pauporte, I, additional, Faure Mercier, C, additional, Paget-Bailly, S, additional, Henriques, J, additional, and Grouin, J-M, additional

Published
2019
Full Text
View/download PDF

16. Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD

Author

Aparicio, T., primary, Darut Jouve, A., additional, Khemissa, F., additional, Montérymard, C., additional, Artru, P., additional, Cany, L., additional, Romano, O., additional, Valenza, B., additional, Le Foll, C., additional, Delbaldo, C., additional, Falandry, C., additional, Duluc, M., additional, Rinaldi, Y., additional, Legoux, J.L., additional, Ben Abdelghani, M., additional, Assenat, E., additional, Dhooge, M., additional, Smith, D., additional, Des Guetz, G., additional, and Lepage, C., additional

Published
2018
Full Text
View/download PDF

17. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Aparicio, Thomas, primary, Ducreux, Michel, additional, Faroux, Roger, additional, Barbier, Emilie, additional, Manfredi, Sylvain, additional, Lecomte, Thierry, additional, Etienne, Pierre-Luc, additional, Bedenne, Laurent, additional, Bennouna, Jaafar, additional, Phelip, Jean-Marc, additional, François, Eric, additional, Michel, Pierre, additional, Legoux, Jean-Louis, additional, Gasmi, Mohamed, additional, Breysacher, Gilles, additional, Rougier, Philippe, additional, De Gramont, Aimery, additional, Lepage, Come, additional, Bouché, Olivier, additional, Seitz, Jean-François, additional, Adenis, A., additional, Alessio, A., additional, Aouakli, A., additional, Azzedine, A., additional, Bedjaoui, A., additional, Bidault, A., additional, Blanchi, A., additional, Botton, A., additional, Cadier-Lagnes, A., additional, Fatisse, A., additional, Gagnaire, A., additional, Gilbert, A., additional, Gueye, A., additional, Hollebecque, A., additional, Lemaire, A., additional, Mahamat, A., additional, Marre, A., additional, Patenotte, A., additional, Rotenberg, A., additional, Roussel, A., additional, Thirot-Bidault, A., additional, Votte, A., additional, Weber, A., additional, Zaanan, A., additional, Dupont-Gossart, A.C., additional, Villing, A.L., additional, Queuniet, A.M., additional, Coudert, B., additional, Denis, B., additional, Garcia, B., additional, Lafforgue, B., additional, Landi, B., additional, Leduc, B., additional, Linot, B., additional, Paillot, B., additional, Rhein, B., additional, Winkfield, B., additional, Barberis, C., additional, Becht, C., additional, Belletier, C., additional, Berger, C., additional, Bineau, C., additional, Borel, C., additional, Brezault, C., additional, Buffet, C., additional, Cornila, C., additional, Couffon, C., additional, De La Fouchardière, C., additional, Giraud, C., additional, Lecaille, C., additional, Lepere, C., additional, Lobry, C., additional, Locher, C., additional, Lombard-Bohas, C., additional, Paoletti, C., additional, Platini, C., additional, Rebischung, C., additional, Sarda, C., additional, Vilain, C., additional, Briac-Levaché, C., additional, Auby, D., additional, Baudet-Klepping, D., additional, Bechade, D., additional, Besson, D., additional, Cleau, D., additional, Festin, D., additional, Gargot, D., additional, Genet, D., additional, Goldfain, D., additional, Luet, D., additional, Malka, D., additional, Peré-Vergé, D., additional, Pillon, D., additional, Sevin-Robiche, D., additional, Smith, D., additional, Soubrane, D., additional, Tougeron, D., additional, Zylberait, D., additional, Carola, E., additional, Cuillerier, E., additional, Dorval Danquechin, E., additional, Echinard, E., additional, Janssen, E., additional, Maillard, E., additional, Mitry, E., additional, Norguet-Monnereau, E., additional, Suc, E., additional, Terrebonne, E., additional, Zrihen, E., additional, Pariente, E.A., additional, Almaric, F., additional, Audemar, F., additional, Bonnetain, F., additional, Desseigne, F., additional, Dewaele, F., additional, Di Fiore, F., additional, Ghiringhelli, F., additional, Husseini, F., additional, Khemissa, F., additional, Kikolski, F., additional, Morvan, F., additional, Petit-Laurent, F., additional, Riot, F., additional, Subtil, F., additional, Zerouala-Boussaha, F., additional, Caroli-Bosc, F.X., additional, Boilleau-Jolimoy, G., additional, Bordes, G., additional, Cavaglione, G., additional, Coulanjon, G., additional, Deplanque, G., additional, Gatineau-Saillant, G., additional, Goujon, G., additional, Medinger, G., additional, Roquin, G., additional, Brixi-Benmansour, H., additional, Castanie, H., additional, Lacroix, H., additional, Maechel, H., additional, Perrier, H., additional, Salloum, H., additional, Senellart, H., additional, Baumgaertner, I., additional, Cumin, I., additional, Graber, I., additional, Trouilloud, I., additional, Boutin, J., additional, Butel, J., additional, Charneau, J., additional, Cretin, J., additional, Dauba, J., additional, Deguiral, J., additional, Egreteau, J., additional, Ezenfis, J., additional, Forestier, J., additional, Goineau, J., additional, Lacourt, J., additional, Lafon, J., additional, Martin, J., additional, Meunier, J., additional, Moreau, J., additional, Provencal, J., additional, Taieb, J., additional, Thaury, J., additional, Tuaillon, J., additional, Vergniol, J., additional, Villand, J., additional, Vincent, J., additional, Volet, J., additional, Bachet, J.B., additional, Barbare, J.C., additional, Souquet, J.C., additional, Grangé, J.D., additional, Dor, J.F., additional, Paitel, J.F., additional, Jouve, J.L., additional, Raoul, J.L., additional, Cheula, J.M., additional, Gornet, J.M., additional, Sabate, J.M., additional, Vantelon, J.M., additional, Vaillant, J.N., additional, Aucouturier, J.P., additional, Barbieux, J.P., additional, Herr, J.P., additional, Lafargue, J.P., additional, Lagasse, J.P., additional, Latrive, J.P., additional, Plachot, J.P., additional, Ramain, J.P., additional, Robin, J.P., additional, Spano, J.P., additional, Douillard, J.Y., additional, Beerblock, K., additional, Bouhier-Leporrier, K., additional, Slimane Fawzi, K., additional, Cany, L., additional, Chone, L., additional, Dahan, L., additional, Gasnault, L., additional, Rob, L., additional, Stefani, L., additional, Wander, L., additional, Baconnier, M., additional, Ben Abdelghani, M., additional, Benchalal, M., additional, Blasquez, M., additional, Carreiro, M., additional, Charbit, M., additional, Combe, M., additional, Duluc, M., additional, Fayolle, M., additional, Gignoux, M., additional, Giovannini, M., additional, Glikmanas, M., additional, Mabro, M., additional, Mignot, M., additional, Mornet, M., additional, Mousseau, M., additional, Mozer, M., additional, Pauwels, M., additional, Pelletier, M., additional, Porneuf, M., additional, Ramdani, M., additional, Schnee, M., additional, Tissot, M., additional, Zawadi, M., additional, Clavero-Fabri, M.C., additional, Gouttebel, M.C., additional, Kaminsky, M.C., additional, Galais, M.P., additional, Abdelli, N., additional, Barrière, N., additional, Bouaria, N., additional, Bouarioua, N., additional, Delas, N., additional, Gérardin, N., additional, Hess-Laurens, N., additional, Stremsdoerfer, N., additional, Berthelet, O., additional, Boulat, O., additional, Capitain, O., additional, Favre, O., additional, Amoyal, P., additional, Bergerault, P., additional, Burtin, P., additional, Cassan, P., additional, Chatrenet, P., additional, Chiappa, P., additional, Claudé, P., additional, Couzigou, P., additional, Feydy, P., additional, Follana, P., additional, Geoffroy, P., additional, Godeau, P., additional, Hammel, P., additional, Laplaige, P., additional, Lehair, P., additional, Martin, P., additional, Novello, P., additional, Pantioni, P., additional, Pienkowski, P., additional, Pouderoux, P., additional, Prost, P., additional, Ruszniewski, P., additional, Souillac, P., additional, Texereau, P., additional, Thévenet, P., additional, Haineaux, P.A., additional, Benoit, R., additional, Coriat, R., additional, Lamy, R., additional, Mackiewicz, R., additional, Beorchia, S., additional, Chaussade, S., additional, Hiret, S., additional, Jacquot, S., additional, Lavau Denes, S., additional, Montembault, S., additional, Nahon, S., additional, Nasca, S., additional, Nguyen, S., additional, Oddou-Lagraniere, S., additional, Pesque-Penaud, S., additional, Fratte, S.P., additional, Chatellier, T., additional, Mansourbakht, T., additional, Morin, T., additional, Walter, T., additional, Boige, V., additional, Bourgeois, V., additional, Derias, V., additional, Guérin-Meyer, V., additional, Hautefeuille, V., additional, Jestin Le Tallec, V., additional, Lorgis, V., additional, Quentin, V., additional, Sebbagh, V., additional, Veuillez, V., additional, Adhoute, X., additional, Coulaud, X., additional, Becouarn, Y., additional, Coscas, Y., additional, Courouble, Y., additional, Le Bricquir, Y., additional, Molin, Y., additional, Rinaldi, Y., additional, Lam, Y.H., additional, and Ladhib, Z., additional

Published
2018
Full Text
View/download PDF

18. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

Author

Lepage, C., primary, Phelip, J.-M., additional, Cany, L., additional, Maillard, E., additional, Lievre, A., additional, Chatellier, T., additional, Faroux, R., additional, Duchmann, J.-C., additional, Ben Abdelghani, M., additional, Breysacher, G., additional, Geoffroy, P., additional, Pere-Verge, D., additional, Pelaquier, A., additional, Pillon, D., additional, Ezenfis, J., additional, Rinaldi, Y., additional, Darut-Jouve, A., additional, Duluc, M., additional, Adenis, A., additional, and Bouché, O., additional

Published
2016
Full Text
View/download PDF

20. 466P - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD

Author

Aparicio, T., Darut Jouve, A., Khemissa, F., Montérymard, C., Artru, P., Cany, L., Romano, O., Valenza, B., Le Foll, C., Delbaldo, C., Falandry, C., Duluc, M., Rinaldi, Y., Legoux, J.L., Ben Abdelghani, M., Assenat, E., Dhooge, M., Smith, D., Des Guetz, G., and Lepage, C.

Published
2018
Full Text
View/download PDF

22. 483P - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

Author

Lepage, C., Phelip, J.-M., Cany, L., Maillard, E., Lievre, A., Chatellier, T., Faroux, R., Duchmann, J.-C., Ben Abdelghani, M., Breysacher, G., Geoffroy, P., Pere-Verge, D., Pelaquier, A., Pillon, D., Ezenfis, J., Rinaldi, Y., Darut-Jouve, A., Duluc, M., Adenis, A., and Bouché, O.

Published
2016
Full Text
View/download PDF

23. Nutritional Advices in Older Patients at Risk for Malnutrition During Chemotherapy for Cancer: No Effect on Mortality Decreased Rate or Severe Infections. Multicentre Inogad Study

Author

Bourdel-Marchasson, I., primary, Durrieu, J., additional, Doussau, A., additional, Germain, C., additional, Blanc, J.-F., additional, Lahmar, C., additional, Dauba, J., additional, Terrebonne, E., additional, Lecaille, C., additional, Ceccaldi, J., additional, Cany, L., additional, Lavau-Denes, S., additional, Chomy, F., additional, Houede, N., additional, Soubeyran, P., additional, Blanc-Bisson, C., additional, and Fonck, M., additional

Published
2013
Full Text
View/download PDF

24. PP111-SUN THE EFFECTS OF NUTRITIONAL ADVICES IN OLDER PATIENTS AT RISK FOR MALNUTRITION DURING CHEMOTHERAPY FOR CANCER ON THE QUALITY OF INTAKES. MULTICENTRE INOGAD STUDY

Author

Bourdel-Marchasson, I., primary, Durrieu, J., additional, Doussau, A., additional, Germain, C., additional, Blanc, J.-F., additional, Lahmar, C., additional, Dauba, J., additional, Terrebonne, E., additional, Lécaille, C., additional, Ceccaldi, J., additional, Cany, L., additional, Lavau-Denes, S., additional, Houdé, N., additional, Chomy, F., additional, Soubeyran, P., additional, Blanc-Bisson, C., additional, and Fonck, M., additional

Published
2013
Full Text
View/download PDF

25. OP037 NUTRITIONAL ADVICES IN OLDER PATIENTS AT RISK FOR MALNUTRITION DURING CHEMOTHERAPY FOR CANCER: NO EFFECT ON MORTALITY DECREASED RATE OF SEVERE INFECTIONS. MULTICENTRE INOGAD STUDY

Author

Bourdel-Marchasson, I., primary, Blanc-Bisson, C., additional, Doussau, A., additional, Germain, C., additional, Blanc, J.F., additional, Lahmar, C., additional, Dauba, J., additional, Terrebonne, E., additional, Lecaille, C., additional, Ceccaldi, J., additional, Cany, L., additional, Lavau-Denes, S., additional, Houede, N., additional, Chomy, F., additional, Durrieu, J., additional, and Fonck, M., additional

Published
2012
Full Text
View/download PDF

26. Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

Author

Pivot, X., primary, Romieu, G., additional, Bonnefoi, H., additional, Pierga, J.-Y., additional, Kerbrat, P., additional, Guastalla, J.-P., additional, Lortholary, A., additional, Espié, M., additional, Fumoleau, P., additional, Serin, D., additional, Jacquin, J.-P., additional, Jouannaud, C., additional, Rios, M., additional, Abadie-Lacourtoisie, S., additional, Tubiana-Mathieu, N., additional, Cany, L., additional, Catala, S., additional, Khayat, D., additional, Pauporte, I., additional, and Kramar, A., additional

Published
2012
Full Text
View/download PDF

28. Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

Author

Roché, H., primary, Allouache, D., additional, Romieu, G., additional, Bourgeois, H., additional, Canon, J., additional, Serin, D., additional, Viens, P., additional, Mauriac, L., additional, Monnier, A., additional, Vindevoghel, A., additional, Dohollou, N., additional, Luporsi, E., additional, Ferrero, J., additional, Audhuy, B., additional, Dopchie, C., additional, Cany, L., additional, Brain, E., additional, Jimenez, M., additional, Roca, L., additional, and Spielmann, M., additional

Published
2009
Full Text
View/download PDF

32. [Adverse effects of interleukin 2]

Author

Alain Ravaud, Negrier S, Lakdja F, Mercatello A, Cany L, Coronel B, Jy, Ranchere, Bécouarn Y, Bn, Bui, and Philip T

Subjects
Dose-Response Relationship, Drug, Animals, Humans, Interleukin-2
Abstract

Interleukin 2, has frequent and important side effects. Toxic effects observed are systemic (fever, chills, malaise), hemodynamic (capillary leak syndrome, hypotension), cardiac (arrhythmia, infarction), renal (renal dysfunction), infectious (septicemia), cutaneous, hematologic, gastrointestinal, endocrinologic and metabolic. Side effects are dose-dependent, generally reversible, with a mortality from 1 to 3%. Regimens of administration and other cytokine combinations affect interleukin 2 toxicity. If the treatment of these side effects is well known, selection of patients and specialized care unit remain always necessary.

Published
1991

33. O14 Screening of elderly patient with cancer for early death risk. Results of a prospective multicentric study of 364 patients under chemotherapy

Author

Soubeyran, P., primary, Rainfray, M., additional, Mathoulin-Pelissier, S., additional, Blanc-Bisson, C., additional, Mertens, C., additional, Blanc, J.F., additional, Ravaud, A., additional, Ceccaldi, J., additional, Imbert, Y., additional, Vogt, L., additional, Dauba, J., additional, Pallis, R., additional, Cany, L., additional, Buy, E., additional, Andria, F., additional, Adhoute, X., additional, Chomy, F., additional, and Fonck, M., additional

Published
2006
Full Text
View/download PDF

34. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (CPT-11 + oxaliplatin [IRINOX]) and two standard arms (LV5-FU2 + CPT-11 [FOLFIRI], LV5-FU2 + oxaliplatin [FOLFOX]) in first line metastatic colorectal cancer (MCRC) (FNCLCC Accord 08)

Author

Becouarn, Y., primary, Ychou, M., additional, Boucher, E., additional, Adenis, A., additional, Cany, L., additional, Jacob, J., additional, Cvitkovic, F., additional, Thezenas, S., additional, and Montoto-Grillot, C., additional

Published
2006
Full Text
View/download PDF

36. Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

Author

Mauriac, L, primary, Luporsi, E, additional, Cutuli, B, additional, Fourquet, A, additional, Garbay, J R, additional, Giard, S, additional, Spyratos, F, additional, Sigal-Zafrani, B, additional, Dilhuydy, J M, additional, Acharian, V, additional, Balu-Maestro, C, additional, Blanc-Vincent, M P, additional, Cohen-Solal, C, additional, De Lafontan, B, additional, Dilhuydy, M H, additional, Duquesne, B, additional, Gilles, R, additional, Lesur, A, additional, Shen, N, additional, Cany, L, additional, Dagousset, I, additional, Gaspard, M H, additional, Hoarau, H, additional, Hubert, A, additional, Monira, M H, additional, Perrié, N, additional, and Romieu, G, additional

Published
2003
Full Text
View/download PDF

37. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

Author

Ravaud, A, primary, Chevreau, C, additional, Cany, L, additional, Houyau, P, additional, Dohollou, N, additional, Roché, H, additional, Soubeyran, P, additional, Bonichon, F, additional, Mihura, J, additional, Eghbali, H, additional, Tabah, I, additional, and Bui, B N, additional

Published
1998
Full Text
View/download PDF

48. Clinical practice guidelines: Standards, options and recommendations - Managing palliative chemotherapy in primary health care of patients with metastatic colorectal cancer (Update 2003),Recommandations pour la pratique clinique: Mise à jour 2003 des standards, options et recommandations pour la prise en charge par chimiothérapie palliative de première ligne des patients atteints d'un cancer colorectal métastatique

Author

Conroy, T., Gory-Delabaere, G., Adenis, A., Bosquet, L., Bouche, O., Louvet, C., Mitry, E., Becouarn, Y., Ducreux, M., Etienne, P. L., Merrouche, Y., Monges, G., Rougier, P., Bosset, J. F., Artru, P., Auclerc, G., Borie, F., Botton, A., Cany, L., Cellier, P., Chiche, L., Clouet, O., Dabouis, G., Gramont, A., Dorval, E., Dubois, J. B., Economides, F., Elias, D., Fraisse, J., Gilly, F., Guichard, F., Haegele, P., Jacob, J. H., hubert johanet, Langlois, D., Lauche, H., Luet, D., Maingon, P., Marchal, C., Maton, O., Nguyen, T. D., Orfeuvre, H., Pecking, A., Pignon, J. P., Platini, C., Pradere, B., Reboul, F., Roth, A., Rothe-Thomas, F., Seitz, J. F., Soubeyran, I., Troufléau, P., Tubiana-Mathieu, N., Wolff, P., Philip, T., Fervers, B., Bey, P., Maigne, D., Bataillard, A., Haugh, M., Farsi, F., Luporsi, E., Theobald, S., Fabre, N., Rousmans, S., Brusco, S., Carretier, J., Delavigne, V., Leichtnam-Dugarin, L., Guillo, S., Guy, A. G., Debuiche, S., Borges-Paninho, H., Esteves, E., Gouvrit, D., Pretet, L., and Sabatier, E.

49. [Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult]

Author

Cany L, Nb, Bui, Stöckle E, Jm, Coindre, Kantor G, and Alain Ravaud

Subjects
Adult, Male, Adolescent, Dose-Response Relationship, Drug, Age Factors, Sarcoma, Soft Tissue Neoplasms, Middle Aged, Combined Modality Therapy, Actuarial Analysis, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Aged, Neoplasm Staging
Abstract

Between 1980 and 1990, 64 adults with a locally advanced soft tissue sarcoma, but without metastasis, were treated with neoadjuvant chemotherapy before conservative local treatment. Tumour localizations were limbs in 26 patients (40.6%) and other parts of the body in 38 patients (59.4%). Moreover, 27 patients had bone and/or vasculo-nervous axis involvement. Response to chemotherapy wasor = 50% for 23 patients (37.7%) with 3 complete remissions,50% for 36 patients and only 2 tumours progressed during chemotherapy. Conservative surgery was thus carried out for 51 patients (79.7%), 11 received external radiotherapy only. At the end of treatment, 49 patients (76.5%) were in complete remission. With a median follow-up of 76 months (range: 25 to 147), 25 patients are alive with no evolutive disease. For the whole population, the actuarial 5-year overall survival is 33.8%. Among the patients who were in complete remission at the end of therapy, 15 developed local recurrences (with metastasis for 7 patients) and 10 became metastatic. Actuarial 5-year overall survival for this subset of patients is 44.8%.

50. Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.

Author

Aparicio T, Bouché O, Etienne PL, Barbier E, Mineur L, Desgrippes R, Guérin-Meyer V, Hocine F, Martin J, Le Brun-Ly V, Cretin J, Desramé J, Rinaldi Y, Cany L, Falandry C, Lefevre LB, Marous M, Terrebonne E, Mosser L, Turpin J, Turpin A, Bauguion L, Reichling C, Van den Eynde M, Carola E, and Hiret S

Subjects
Humans, Aged, Oxaliplatin therapeutic use, Fluorouracil therapeutic use, Capecitabine adverse effects, Disease-Free Survival, Chemotherapy, Adjuvant adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neoplasm Staging, Leucovorin therapeutic use, Colonic Neoplasms drug therapy, Colonic Neoplasms surgery, Colonic Neoplasms pathology, Adenocarcinoma drug therapy, Adenocarcinoma surgery, Adenocarcinoma etiology, Frailty
Abstract

Background: Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection, but this improvement was not demonstrated in older patients., Methods: The purpose of ADAGE-PRODIGE 34, randomized open phase III trial is to compare in patients over 70 years oxaliplatin plus fluoropyrimidine with fluoropyrimidine alone in fit patients (Group 1) and fluoropyrimidine with observation in frail patients (Group 2) after resection of stage III colon adenocarcinoma. We report a preliminary tolerance analysis on 50% of the first patients enrolled., Results: The analysis was conducted on 491 patients (378 in Group 1 and 113 in Group 2). Patients in Group 2 were older and showed more frailty criteria than those in Group 1. Cumulative grade 3-5 toxicities were more frequent in patients treated with oxaliplatin in Group 1 or with fluoropyrimidine in Group 2 than in patients treated with fluoropyrimidine in Group 1. At least one course was deferred in more than half of the patients in all groups. Early treatment cessation was more frequent in Group 2., Conclusion: No safety concerns were raised for the continuation of accrual. The frailty criteria distribution suggests that the investigator's evaluation for group allocation was accurate., Competing Interests: Conflict of interest Thomas Aparicio declared Honoraria from Sanofi, Roche, Amgen, Servier, Pierre Fabre and Astra Zeneca; Consultancy / Advisory role for Bioven, Pierre Fabre, MSD and Sirtec; Travel accommodations from Roche. Olivier Bouché reports personal fees as a speaker and/or in an advisory role from Merck KGaA, Roche, Bayer, Astra-Zeneca, Grunenthal, MSD, Amgen, Sanofi, Servier, and Pierre Fabre, outside the submitted work. Pierre-Luc Etienne declared Travels and congress accomodations Roche, BMS, Servier, and research honoraria BMS Claire Falandry reported personal fees from Leo Pharma, Pfizer, MSD Oncology, Teva, AstraZeneca, Baxter, Eisai, Janssen Oncology, Novartis, Chugai Pharma, and Astellas Pharma outside the submitted work; grants from Chugai Pharma, Pfizer, Pierre Fabre, and Astellas Pharma outside the submitted work; and non-financial support from Janssen Oncology, Pierre Fabre, AstraZeneca, and Leo Pharma outside the submitted work. Eric Terrebone declared Honoraria from IPSEN, Servier Anthony Turpin declared Honoraria from Pierre Fabre, Servier, Viatris Marc Van den Eynde declared Honoraria from Servier, BMS, MSD, Merck and Amgen. Travel accommodations from MSD. Elisabeth Carola declared Honoraria from EISAI, Pierre Fabre, Pfizer, AMGEN, Lilly, Seagen Novartis, Sanofi. All remaining authors have declared no conflicts of interest, (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results